Mirum Pharmaceuticals (08D) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

08D Analyst Ratings

Strong Buy

13 Buy

0 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Mirum

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

08D Stock 12 Month Forecast

Average Price Target

€128.49

▲(61.06% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Mirum Pharmaceuticals in the last 3 months. The average price target is €128.49 with a high forecast of €161.71 and a low forecast of €109.26. The average price target represents a 61.06% change from the last price of €79.78.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"40":"€40","101":"€101","162":"€162","70.5":"€70.5","131.5":"€131.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":161.7093288,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€161.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":128.49335856,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€128.49</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":109.26306,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€109.26</span>\n  </div></div>","useHTML":true}}],"tickPositions":[40,70.5,101,131.5,162],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,100.3,105.02379452307692,109.74758904615385,114.47138356923077,119.19517809230769,123.91897261538462,128.64276713846155,133.36656166153847,138.0903561846154,142.8141507076923,147.53794523076925,152.26173975384614,156.9855342769231,{"y":161.7093288,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,100.3,102.46871988923077,104.63743977846154,106.8061596676923,108.97487955692307,111.14359944615384,113.31231933538461,115.48103922461539,117.64975911384614,119.81847900307692,121.98719889230769,124.15591878153845,126.32463867076922,{"y":128.49335856,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,100.3,100.98946615384615,101.6789323076923,102.36839846153846,103.05786461538462,103.74733076923077,104.43679692307691,105.12626307692307,105.81572923076922,106.50519538461538,107.19466153846153,107.88412769230769,108.57359384615384,{"y":109.26306,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":41.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.32,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.06,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.3,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€161.71

Average Price Target€128.49

Lowest Price Target€109.26

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Lisa Walter

RBC Capital

€124.12→€129.37

Buy

62.16%

Upside

Reiterated

07/07/26

Mirum Pharmaceuticals price target raised to $148 from $142 at RBC CapitalMirum Pharmaceuticals price target raised to $148 from $142 at RBC Capital

Jessica Fye

J.P. Morgan

€100.52→€109.26

Buy

36.96%

Upside

Reiterated

07/02/26

Mirum Pharmaceuticals price target raised to $125 from $115 at JPMorganMirum Pharmaceuticals price target raised to $125 from $115 at JPMorgan

Jonathan Wolleben

Citizens JMP

€122.37→€127.62

Buy

59.96%

Upside

Reiterated

06/15/26

Mirum Pharmaceuticals price target raised to $146 from $140 at CitizensMirum Pharmaceuticals price target raised to $146 from $140 at Citizens

Swayampakula Ramakanth

H.C. Wainwright

€161.71

Buy

102.69%

Upside

Reiterated

06/15/26

Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (NYSE: DGX), Celldex (NASDAQ: CLDX) and Mirum Pharmaceuticals (NASDAQ: MIRM)

Michael Ulz

Morgan Stanley

€131.12

Buy

64.35%

Upside

Reiterated

06/15/26

Mirum Therapeutics: Strong FOP Data and Priority Review Support Buy Rating and Unchanged $150 Price Target

Yigal Nochomovitz

Citi

€126.75

Buy

58.87%

Upside

Reiterated

06/14/26

Buy Rating Reiterated on Mirum Pharmaceuticals as Zilurgisertib Data De-Risk Pipeline; $145 Price Target Unchanged with ~46% Upside Potential

Kalpit Patel

Wolfe Research

€126.75

Buy

58.87%

Upside

Initiated

05/19/26

Mirum Pharmaceuticals initiated with an Outperform at Wolfe ResearchMirum Pharmaceuticals initiated with an Outperform at Wolfe Research

Mani Foroohar

Leerink Partners

€131.12→€134.61

Buy

68.73%

Upside

Reiterated

05/15/26

Leerink Partners Remains a Buy on Mirum Pharmaceuticals (MIRM)

Gavin Clark-Gartner

Evercore ISI

€118→€120.63

Buy

51.20%

Upside

Reiterated

05/07/26

Mirum Pharmaceuticals price target raised to $138 from $135 at Evercore ISIMirum Pharmaceuticals price target raised to $138 from $135 at Evercore ISI

Joseph Thome

TD Cowen

€109.26→€126.75

Buy

58.87%

Upside

Assigned

05/07/26

Analysts Are Bullish on These Healthcare Stocks: InflaRx (IFRX), Mirum Pharmaceuticals (MIRM)

Ryan Deschner

Raymond James

€143.35→€144.23

Buy

80.78%

Upside

Reiterated

05/07/26

Mirum Pharmaceuticals price target raised to $165 from $164 at Raymond JamesMirum Pharmaceuticals price target raised to $165 from $164 at Raymond James

James Condulis

Stifel Nicolaus

€113.63→€118.88

Buy

49.01%

Upside

Reiterated

05/07/26

Stifel Nicolaus Sticks to Their Buy Rating for Mirum Pharmaceuticals (MIRM)

Brian Skorney

Robert W. Baird

€97.9→€112.76

Buy

41.34%

Upside

Reiterated

05/07/26

Mirum Pharmaceuticals price target raised to $129 from $112 at BairdMirum Pharmaceuticals price target raised to $129 from $112 at Baird

Joshua Schimmer

Cantor Fitzgerald

€122.37

Buy

53.39%

Upside

Reiterated

04/09/26

Cantor Fitzgerald Sticks to Their Buy Rating for Mirum Pharmaceuticals (MIRM)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Lisa Walter

RBC Capital

€124.12→€129.37

Buy

62.16%

Upside

Reiterated

07/07/26

Mirum Pharmaceuticals price target raised to $148 from $142 at RBC CapitalMirum Pharmaceuticals price target raised to $148 from $142 at RBC Capital

Jessica Fye

J.P. Morgan

€100.52→€109.26

Buy

36.96%

Upside

Reiterated

07/02/26

Mirum Pharmaceuticals price target raised to $125 from $115 at JPMorganMirum Pharmaceuticals price target raised to $125 from $115 at JPMorgan

Jonathan Wolleben

Citizens JMP

€122.37→€127.62

Buy

59.96%

Upside

Reiterated

06/15/26

Mirum Pharmaceuticals price target raised to $146 from $140 at CitizensMirum Pharmaceuticals price target raised to $146 from $140 at Citizens

Swayampakula Ramakanth

H.C. Wainwright

€161.71

Buy

102.69%

Upside

Reiterated

06/15/26

Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (NYSE: DGX), Celldex (NASDAQ: CLDX) and Mirum Pharmaceuticals (NASDAQ: MIRM)

Michael Ulz

Morgan Stanley

€131.12

Buy

64.35%

Upside

Reiterated

06/15/26

Mirum Therapeutics: Strong FOP Data and Priority Review Support Buy Rating and Unchanged $150 Price Target

Yigal Nochomovitz

Citi

€126.75

Buy

58.87%

Upside

Reiterated

06/14/26

Buy Rating Reiterated on Mirum Pharmaceuticals as Zilurgisertib Data De-Risk Pipeline; $145 Price Target Unchanged with ~46% Upside Potential

Kalpit Patel

Wolfe Research

€126.75

Buy

58.87%

Upside

Initiated

05/19/26

Mirum Pharmaceuticals initiated with an Outperform at Wolfe ResearchMirum Pharmaceuticals initiated with an Outperform at Wolfe Research

Mani Foroohar

Leerink Partners

€131.12→€134.61

Buy

68.73%

Upside

Reiterated

05/15/26

Leerink Partners Remains a Buy on Mirum Pharmaceuticals (MIRM)

Gavin Clark-Gartner

Evercore ISI

€118→€120.63

Buy

51.20%

Upside

Reiterated

05/07/26

Mirum Pharmaceuticals price target raised to $138 from $135 at Evercore ISIMirum Pharmaceuticals price target raised to $138 from $135 at Evercore ISI

Joseph Thome

TD Cowen

€109.26→€126.75

Buy

58.87%

Upside

Assigned

05/07/26

Analysts Are Bullish on These Healthcare Stocks: InflaRx (IFRX), Mirum Pharmaceuticals (MIRM)

Ryan Deschner

Raymond James

€143.35→€144.23

Buy

80.78%

Upside

Reiterated

05/07/26

Mirum Pharmaceuticals price target raised to $165 from $164 at Raymond JamesMirum Pharmaceuticals price target raised to $165 from $164 at Raymond James

James Condulis

Stifel Nicolaus

€113.63→€118.88

Buy

49.01%

Upside

Reiterated

05/07/26

Stifel Nicolaus Sticks to Their Buy Rating for Mirum Pharmaceuticals (MIRM)

Brian Skorney

Robert W. Baird

€97.9→€112.76

Buy

41.34%

Upside

Reiterated

05/07/26

Mirum Pharmaceuticals price target raised to $129 from $112 at BairdMirum Pharmaceuticals price target raised to $129 from $112 at Baird

Joshua Schimmer

Cantor Fitzgerald

€122.37

Buy

53.39%

Upside

Reiterated

04/09/26

Cantor Fitzgerald Sticks to Their Buy Rating for Mirum Pharmaceuticals (MIRM)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ASNDAscendis Pharma

CRBPCorbus Pharmaceuticals

ACHVAchieve Life Sciences

CELCCelcuity

GKOSGlaukos

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Mirum Pharmaceuticals

3 Months

Michael UlzMorgan Stanley

Success Rate

15/19 ratings generated profit

Average Return

+15.82%

Copying Michael Ulz's trades and holding each position for 3 Months would result in 78.95% of your transactions generating a profit, with an average return of +15.82% per trade.

1 Year

Gavin Clark-GartnerEvercore ISI

Success Rate

16/16 ratings generated profit

Average Return

+67.51%

Copying Gavin Clark-Gartner's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +67.51% per trade.

2 Years

Jonathan WollebenCitizens JMP

Success Rate

22/22 ratings generated profit

Average Return

+151.97%

Copying Jonathan Wolleben's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +151.97% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

08D Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 08D has received 25 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 08D average Analyst price target in the past 3 months is 128.49.

Each month's total comprises the sum of three months' worth of ratings.

08D Financial Forecast

08D Earnings Forecast

Next quarter’s earnings estimate for 08D is -€0.64 with a range of -€1.29 to -€0.36. The previous quarter’s EPS was -€11.78. 08D beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 08D has Performed in-line its overall industry.

08D Sales Forecast

Next quarter’s sales forecast for 08D is €145.62M with a range of €140.49M to €151.75M. The previous quarter’s sales results were €140.22M. 08D beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year 08D has Performed in-line its overall industry.

08D Stock Forecast FAQ

What is DE:08D’s average 12-month price target, according to analysts?

Based on analyst ratings, Mirum Pharmaceuticals’s 12-month average price target is 128.49.

What is DE:08D’s upside potential, based on the analysts’ average price target?

Mirum Pharmaceuticals has 61.06% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Mirum Pharmaceuticals a Buy, Sell or Hold?

Mirum Pharmaceuticals has a consensus rating of Strong Buy, which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.

What is Mirum Pharmaceuticals’s share price target?

The average share price target for Mirum Pharmaceuticals is 128.49. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €161.71 ,and the lowest forecast is €109.26. The average share price target represents 61.06% Increase from the current price of €79.78.

What do analysts say about Mirum Pharmaceuticals?

Mirum Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of Mirum Pharmaceuticals?

To buy shares of DE:08D, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Mirum Pharmaceuticals (08D) Stock Forecast & Price Target

08D Analyst Ratings

08D Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Mirum Pharmaceuticals

08D Analyst Recommendation Trends

08D Financial Forecast

08D Earnings Forecast

08D Sales Forecast

08D Stock Forecast FAQ

Detailed List of Analyst Forecasts